CVRx Announces Positive News on Outpatient Payment for Barostim
This proposal follows two other positive developments in the last nine months relating to reimbursement rates. As of Oct. 1, 2024, Barostim was assigned to a higher paying MS-DRG for inpatient procedures. In that same month it was announced that Barostim will transition from Category III to Category I CPT codes for physician payments as of Jan. 1, 2026. These reimbursement updates underscore the clinical value of Barostim and reinforce its role in the heart failure care continuum.
'We appreciate CMS' proposal to keep Barostim in APC 1580, ensuring appropriate payment for the Barostim implant procedure,' said Kevin Hykes, President and CEO of CVRx. 'These reimbursement updates, along with the favorable proposed payment levels included in the recently released physician fee schedule, allow us to continue our progress toward expanding access to Barostim for patients suffering from heart failure with reduced ejection fraction, which we believe will help support its broader market adoption and long-term growth.'
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements about the proposal to maintain the APC for the Barostim implant procedure and progress toward expanded access to Barostim are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about future events, and are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ from our expectations, including the final OPPS rule, which could differ from the proposed rule, following the public comment period, and the actual impact of the APC on actual reimbursement and patient access. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Media Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@cvrx.com
Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@cvrx.comSign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Alpha Modus Holdings Inc. (NASDAQ: AMOD) Eliminates Variable Rate Debt and Finalizes Capital Structure Cleanup
CHARLOTTE, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings Inc. (NASDAQ: AMOD), a pioneer in AI-driven retail technology, is pleased to announce a significant milestone in its ongoing commitment to long-term shareholder value. As of today, the Company confirms that all variable rate debt associated with the DESPAC process has been fully resolved and extinguished. This achievement marks the culmination of a strategic initiative that has been central to Alpha Modus' financial philosophy over the past six months: preserving the integrity of the company's capital structure and avoiding the use of dilutive derivative instruments that erode shareholder confidence. 'We've been very clear with the market—we will not jeopardize our vision or shareholder value through toxic financing,' said William Alessi, CEO of Alpha Modus. 'Today's announcement reflects our steadfast commitment to that principle. We now operate with a fully streamlined capital structure—clear, investor-aligned, and built to support long-term value creation.' With a clean cap table and no third-party variable rate debt overhang, Alpha Modus enters its next phase of expansion with enhanced appeal to institutional investors, strategic partners, and shareholders focused on long-term value creation. For more information, visit: About Alpha Modus Holdings Modus Holdings Inc. (NASDAQ: AMOD) is redefining the retail experience through its patented AI technologies, intelligent kiosks, and targeted consumer engagement tools. By integrating innovation with infrastructure, Alpha Modus is unlocking new monetization pathways for retailers and fintech providers alike. For more information and to access Alpha Modus' press room, visit: Forward-Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus's actual results may differ from their expectations, estimates, and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus's expectations with respect to future performance. Alpha Modus cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. Contact Information Investor RelationsAlpha Modus Holdings, ir@ Follow us on LinkedIn | Follow us on XError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
CareCloud, Inc. (CCLD): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish thesis on CareCloud, Inc. (CCLD) on Undervalued and undercovered 's Substack by Hugh Navarro. In this article, we will summarize the bulls' thesis on CCLD. CareCloud, Inc. (CCLD)'s share was trading at $2.4 as of 16th July. CCLD's forward P/E was 8.28, respectively according to Yahoo Finance. A doctor utilizing a cloud-based healthcare platform to access patient records. CareCloud (Nasdaq: CCLD) presents a rare opportunity in the healthcare IT sector—a high-margin, recurring-revenue business trading at a deeply discounted valuation with an 18% free cash flow yield. Its core offering is a vertically integrated platform providing Revenue Cycle Management (RCM), Electronic Health Records (EHR), and Practice Management (PM) software to small and medium-sized medical practices. With 67% of revenue from RCM, CareCloud helps practices get paid faster and more efficiently, boasting a denial rate under 3% and up to 94% first-pass claims. The cloud-based system integrates billing, insurance checks, and analytics, differentiating itself with robotic automation and an in-house clearinghouse. Complementing this is a growing AI layer, cirrusAI, which powers real-time clinical note generation, chatbot support for staff, and automated appeals for denied claims. The company is aggressively expanding this AI infrastructure, aiming for 500 engineers by year-end, setting it up for long-term product superiority. Despite an 11% contribution from medical practice management, the real upside lies in the company's scalable tech and a consolidation strategy focused on acquiring customer bases from smaller, less efficient players. CareCloud also benefits from significant NOLs, insulating it from taxes for years. Past selling pressure due to a complex preferred-share structure has left shares undervalued, but a founder-led, 15%-insider-owned management team is now aligned for growth. The sector's rising complexity and demand for automation make CareCloud's solutions increasingly vital. With churn at just 5%, strong embedded pricing power, and multiple growth levers, the stock offers a compelling path to multi-bagger returns, potentially 5x from current levels. Previously we covered a on SANUWAVE Health, Inc. (SNWV) by @rationalformula in May 2025, which highlighted the company's turnaround story, recurring revenue from its FDA-cleared wound care device, and strong operational momentum. The company's stock price has appreciated by approximately 7% since our coverage. This is because the thesis played out with improving financials and execution. This is because demand for its consumables remains strong despite historical challenges. CareCloud author shares a similar view but emphasizes on software-driven efficiency and AI-powered automation as the growth engine in healthcare IT. CareCloud, Inc. (CCLD) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 3 hedge fund portfolios held CCLD at the end of the first quarter which was 3 in the previous quarter. While we acknowledge the potential of CCLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Business Wire
14 minutes ago
- Business Wire
Vistagen to Present at the BTIG Virtual Biotechnology Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be livestreamed for registered investors, and a recording will be available on the BTIG conference portal for conference attendees following the event. If you would like to schedule a one-on-one meeting with Vistagen's management team, please contact your BTIG representative. To join the conference, email uscorporateaccess@ About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, such as vasomotor symptoms (hot flashes) associated with menopause. Connect at